## MRNA: Moderna, Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 4.9% in lower entry zone (4.0-10.0%), top quartile (86th pct) cross-sectional ranking. Short-term MRS_5 (4.2%) confirms momentum alignment. Outperforming sector by 4.4%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($29.13)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 10, Bearish: 0)

**1. Key facts: Moderna announces 2025 achievements; mRNA-1010 shows efficacy**
- Source: TradingView — Track All Markets | 20260105T200807 | Bullish | Relevance: 100%
- Moderna announced its 2025 achievements on January 5, 2026, including multiple regulatory approvals and the launch of three commercial products. The company's mRNA-1010 vaccine demonstrated 26.6% efficacy in adults 50+ and 27.4% in those 65+, supported by positive Phase 3 study results.

**2. Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine**
- Source: Enterprise News | 20260105T190807 | Bullish | Relevance: 100%
- Moderna has announced global regulatory submissions for its investigational seasonal influenza vaccine, mRNA-1010, for adults aged 50 and older. The company has filed for marketing authorization in the U.S., EU, Canada, and Australia, citing positive data from Phase 3 studies that demonstrated superior efficacy and a favorable safety profile. Stéphane Bancel, CEO, highlighted mRNA technology's potential to better match evolving flu strains and support Moderna's growth.

**3. Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine**
- Source: Cape Cod Times | 20260105T170830 | Bullish | Relevance: 100%
- Moderna has submitted regulatory applications for its investigational seasonal influenza vaccine, mRNA-1010, for adults aged 50 and older to authorities in the U.S., EU, Canada, and Australia. This vaccine aims to provide a more agile response to evolving flu strains, addressing concerns about vaccine mismatch. The submissions are supported by positive Phase 3 study data demonstrating both efficacy and a favorable safety profile.

**4. Moderna, searching for a rebound, to seek approval of mRNA flu shot**
- Source: BioPharma Dive | 20260105T165636 | Bullish | Relevance: 100%
- Moderna has filed applications for approval of its mRNA-1010 seasonal flu vaccine in the U.S., Europe, Canada, and Australia, targeting individuals aged 50 and older. This move is part of the company's strategy to rebound from recent setbacks, with the flu shot expected to be a significant revenue driver. The vaccine demonstrated a 27% reduction in influenza illness risk in clinical trials for those 50 and older, and Moderna aims to leverage its mRNA technology for quicker vaccine development against evolving flu strains.

**5. Moderna, Inc. Reports 2025 Achievements and 2026 Outlook**
- Source: TradingView — Track All Markets | 20260105T141528 | Bullish | Relevance: 100%
- Moderna, Inc. (MRNA) announced its 2025 achievements and strategic plans for 2026, highlighting regulatory approvals, the success of mNEXSPIKE, global manufacturing expansion, and pipeline advancements. The company also maintained financial discipline by reducing operating expenses and securing a $1.5 billion loan. These details were officially filed with the SEC on January 5, 2026.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $28 | $30 | -7% |
| 2025-12-12 | Jefferies | $30 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-12-12 | Jefferies | init | Hold |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.26M) |
| Sells | 10 ($0.60M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 10.5% (-1.2%)
- Blackrock Inc.: 7.6% (+3.2%)
- BAILLIE GIFFORD & CO: 5.6% (-1.1%)
- State Street Corpora: 4.4% (-0.9%)
- FMR, LLC: 3.1% (-37.4%)

### Key Risks

1. High short interest (21.7%, 7.0 days to cover): squeeze risk or crowded bearish bet.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 2.44 elevated, pricing in significant growth expectations. Balance sheet: strong liquidity (3.9x), low leverage (D/E 0.30). Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $12.6B |
| Beta | 1.17 |
| 52W Range | $22.28 - $48.92 |
| Short Interest | 21.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.44 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 weakening modestly (-0.5% over 5 days). Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 86th percentile. MRS_5 at 4.2% confirms short-term momentum alignment. AM_20 at 5.1% shows strong absolute momentum above own 20MA. Outperforming sector by 4.4pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 4.92% (CS: 86) | Strong |
| RSI_14 | 60.2 | Neutral |
| MACD Histogram | -0.18 | Bearish |
| vs SMA20 | 1.051x | Above |
| vs SMA50 | 1.179x | Above |
| vs SMA200 | 1.175x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $32.17
- **Stop Loss:** $29.13 (9.4% risk)
- **Target:** $36.73 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 283
- **Position Value:** $9,104.11
- **Portfolio %:** 9.10%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-12 (Est: $-2.73)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-2.18 | $-0.51 | +76.6% |
| 2025Q2 | $-2.97 | $-2.13 | +28.3% |
| 2025Q1 | $-3.18 | $-2.52 | +20.7% |
| 2024Q4 | $-2.76 | $-2.91 | -5.4% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_20*